Immune checkpoint therapy in renal cell carcinoma Journal Article
| Authors: | Lee, C. H.; Motzer, R. J. |
| Article Title: | Immune checkpoint therapy in renal cell carcinoma |
| Abstract: | Renal cell carcinoma (RCC) is a largely chemotherapyresistant disease that is commonly treated with molecularly targeted therapies. Evidence suggests that RCC is also an immune-responsive disease, and checkpoint inhibitors are in active development as agents for the treatment of systemic disease. Programmed cell death 1 (PD-1) is an inhibitory immune checkpoint, and blockade of the PD-1 cascade is an attractive target in RCC. Expression of the ligand for PD-1 in RCC has been shown to be a negative prognostic factor; however, response to PD-1 blockade is not restricted to tumors expressing the ligand for PD-1. Nivolumab is the most completely characterized anti-PD-1 agent in RCC and has been shown to be efficacious as monotherapy. Currently, there are multiple ongoing clinical trials exploring the use of combination therapy with PD-1 blockade. © 2016 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | monotherapy; combination therapy; renal cell carcinoma (rcc); pd-1 cascade |
| Journal Title: | The Cancer Journal |
| Volume: | 22 |
| Issue: | 2 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2016-03-01 |
| Start Page: | 92 |
| End Page: | 95 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000177 |
| PROVIDER: | scopus |
| PUBMED: | 27111903 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 June 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work